20 articles
A large WHO pharmacovigilance analysis reveals which myeloma drugs most strongly signal autonomic, motor, and sensory nerve damage.
Novel BRAF inhibitor mosperafenib demonstrates safety and efficacy in patients with advanced cancers, including those resistant to prior treatments.
Widely-used anesthetic triggers immune system to attack tumors and enhances checkpoint inhibitor therapy effectiveness.
Ketogenic diet metabolite enhances CAR T cell metabolism and tumor control in multiple cancer models
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Nationwide French study reveals benzodiazepine use significantly worsens survival outcomes in lung cancer patients receiving pembrolizumab immunotherapy.
Two common antidepressants cause cholesterol buildup in cancer cell lysosomes, triggering immunogenic cell death that helps immune system fight tumors.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
Scientists develop brain-penetrating drug that makes glioblastoma cells vulnerable to targeted elimination therapy.
Phase I trial of Temab-A reports 15.6% response rate and 74.6% disease control in heavily pretreated metastatic colorectal cancer patients.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
New research reveals how hepatoma cells evade immunotherapy by secreting N1-acetylspermidine to suppress immune function.
Metabolite supplement protects heart from chemo toxicity and enhances tumor suppression in breakthrough dual-action study.
Scientists develop LP-65, a single molecule targeting two cancer pathways simultaneously, showing enhanced anti-tumor effects in lab studies.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
Camizestrant effectively reduces estrogen receptors and tumor growth at just 75mg daily with minimal side effects in breast cancer patients.
A newly identified lipid mediator may explain why immune cells fail to fight MASH-driven liver cancer, opening therapeutic targets.
A novel cell-labeling tool reveals how ERΞ±+ macrophages create immune-excluded niches in bone, blocking T cells from destroying cancer.
Bireociclib plus fulvestrant significantly improved outcomes in advanced hormone-positive breast cancer patients.
